BEIJING, CHINA, August 27, 2012 - MicroConstants China Inc., a Contract Research Organization (CRO) conducting preclinical PK studies and providing full-service early stage clinical trial management in China, has received a renewed Endorsement of Compliance with the OECD Principles of Good Laboratory Practice (GLP) at its newly established facility in Beijing. The Endorsement was initially awarded in May 2011 following an inspection at MicroConstants China’s previous location.
In February, MicroConstants China relocated their laboratory to a new 8,000 square foot facility in the Huilongsen International Science & Technology Park in the Beijing Development Area (BDA) in southeast Beijing. After months of internal testing and qualification of all equipment, the new facility was visited by the Health Care Inspectorate, Ministry of Health, Welfare and Sport of Netherlands for a GLP compliance reassessment. Following a week long inspection in June, the Inspectorate confirmed the new facility is compliant with the OECD Principles of GLP in the areas of analytical chemistry and pharmacokinetic studies and the Endorsement of Compliance was renewed.
“The continued OECD GLP Endorsement, along with the CNAS accreditation received in 2010, exemplifies our pursuit of conducting high quality contract research services to meet global regulatory requirements,” said Dr. Q. David Yang, CEO of MicroConstants China. “We will continue to expand our scope of services and capabilities to meet our clients’ demands.”
“This is truly a historical moment for China and MicroConstants,” said Dr. Gilbert Lam, founder of MicroConstants China and president of MicroConstants, Inc. in San Diego, California. “It reflects our commitment to be the leader in GLP compliance.”
About MicroConstants China Inc.
MicroConstants China Inc. is a Contract Research Organization (CRO) that was established in 2007 by the founder and president of MicroConstants, Inc., a bioanalytical and DMPK specialty CRO in San Diego, California with over a decade of GLP compliance history. Located in Beijing, MicroConstants China provides preclinical and clinical pharmacokinetic analysis, analytical services, and early stage clinical trial management services, including clinical site qualification, trial monitoring, data management, biostatistics, and clinical summary reports to pharmaceutical and biotech companies worldwide. Additionally, the CRO offers QA audit and drug development project management services for preclinical toxicology and pharmacology studies in China. Its bioanalytical laboratory is fully GLP-compliant with USFDA, OECD, Japan MHLW and China SFDA guidelines. For more information about MicroConstants China and the contract research services they provide, please visit http://www.microconstants.com.cn.
For more information, contact:
Jessica Hou
MicroConstants China Inc.
jhou@microconstants.com
Tel: +86 133 1111-8640
